Expansion of guidance for the day 8 initiation dose of paliperidone palmitate to avoid a missed dose by Samtani MN, Nuamah I, Gopal S, Remmerie B, Sliwa JK, Alphs L

Get full text

Incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studies by Gopal S, Liu Y, Alphs L, Savitz A, Nuamah I, Hough D

Get full text

Patients’ Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference Questionnaire by Blackwood C, Sanga P, Nuamah I, Keenan A, Singh A, Mathews M, Gopal S

Get full text

Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population by Savitz AJ, Xu H, Gopal S, Nuamah I, Ravenstijn P, Hough D, Hargarter L

Get full text

Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate by Mathews M, Nuamah I, Savitz AJ, Hough DW, Najarian D, Kim E, Gopal S

Get full text

Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia by Mathews M, Gopal S, Nuamah I, Hargarter L, Savitz AJ, Kim E, Tan W, Soares B, Correll CU

Get full text

Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Ho... by Mathews M, Gopal S, Singh A, Nuamah I, Pungor K, Tan W, Soares B, Kim E, Savitz AJ

Get full text

Relapse and Treatment Adherence in Patients with Schizophrenia Switching from Paliperidone Palmitate Once-Monthly to Three-Monthly Formulation: A Retrospective Health Claims Databa... by Li G, Keenan A, Daskiran M, Mathews M, Nuamah I, Orman C, Joshi K, Singh A, Godet A, Pungor K, Gopal S

Get full text

Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase II... by Savitz AJ, Xu H, Gopal S, Nuamah I, Ravenstijn P, Hough D, Mathews M, Feng Y, Yu L, Takahashi M, Liu D, Wang G, Yoon J, Chen JJ

Get full text